Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
AKR1B1 as a prognostic biomarker of high-grade serous ovarian cancer
ID
Hojnik, Marko
(
Author
),
ID
Kenda Šuster, Nataša
(
Author
),
ID
Smrkolj, Špela
(
Author
),
ID
Sisinger, Damjan
(
Author
),
ID
Frković-Grazio, Snježana
(
Author
),
ID
Verdenik, Ivan
(
Author
),
ID
Lanišnik-Rižner, Tea
(
Author
)
PDF - Presentation file,
Download
(6,42 MB)
MD5: 920A293BA8A0DE460E8FDC8742131FEF
URL - Source URL, Visit
https://www.mdpi.com/2072-6694/14/3/809
Image galllery
Abstract
Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.
Language:
English
Keywords:
high-grade serous ovarian cancer
,
immunohistochemistry
,
survival
,
prognosis
,
biomarker
,
aldo-keto reductase family 1 member B1 (AKR1B1)
,
aldo-keto reductase family 1 member B10 (AKR1B10)
,
resistance
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
15 str.
Numbering:
Vol. 14, iss. 3, art. 809
PID:
20.500.12556/RUL-137350
UDC:
618.1
ISSN on article:
2072-6694
DOI:
10.3390/cancers14030809
COBISS.SI-ID:
96813059
Publication date in RUL:
13.06.2022
Views:
766
Downloads:
125
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Cancers
Shortened title:
Cancers
Publisher:
MDPI
ISSN:
2072-6694
COBISS.SI-ID:
517914137
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
05.02.2022
Secondary language
Language:
Slovenian
Keywords:
serozni rak jajčnikov visoke stopnje
,
imunohistokemija
,
preživetje
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
J3-8212
Name:
Vloga intrakrinega delovanja estrogenov pri hormonsko odvisnih boleznih – pomen za zdravljenje
Funder:
ARRS - Slovenian Research Agency
Project number:
J3-2535
Name:
Vloga androgenov pri hormonsko odvisnih boleznih: pomen za diagnostiko in zdravljenje
Funder:
ARRS - Slovenian Research Agency
Funding programme:
Young researchers
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back